These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 32703252)
1. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. Talebi R; Redberg RF; Ross JS Trials; 2020 Jul; 21(1):675. PubMed ID: 32703252 [TBL] [Abstract][Full Text] [Related]
2. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. Miller JE; Korn D; Ross JS BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214 [TBL] [Abstract][Full Text] [Related]
3. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601 [TBL] [Abstract][Full Text] [Related]
4. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. DeVito NJ; Bacon S; Goldacre B Lancet; 2020 Feb; 395(10221):361-369. PubMed ID: 31958402 [TBL] [Abstract][Full Text] [Related]
5. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA. Swanson MJ; Johnston JL; Ross JS Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308 [TBL] [Abstract][Full Text] [Related]
6. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112 [TBL] [Abstract][Full Text] [Related]
7. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry. Keestra SM; Rodgers F; Lenz D; Osborne R; Bruckner T; Lee S Trials; 2021 Jun; 22(1):375. PubMed ID: 34074329 [TBL] [Abstract][Full Text] [Related]
8. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616 [TBL] [Abstract][Full Text] [Related]
9. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials. Perlmutter AS; Tran VT; Dechartres A; Ravaud P Ann Oncol; 2017 Apr; 28(4):688-695. PubMed ID: 28011448 [TBL] [Abstract][Full Text] [Related]
10. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. Prayle AP; Hurley MN; Smyth AR BMJ; 2012 Jan; 344():d7373. PubMed ID: 22214756 [TBL] [Abstract][Full Text] [Related]
11. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles. Pranić S; Marušić A J Clin Epidemiol; 2016 Feb; 70():26-37. PubMed ID: 26226103 [TBL] [Abstract][Full Text] [Related]
12. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States. Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418 [TBL] [Abstract][Full Text] [Related]
13. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis. Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS BMJ; 2018 May; 361():k2031. PubMed ID: 29794072 [TBL] [Abstract][Full Text] [Related]
14. Compliance with results reporting at ClinicalTrials.gov. Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355 [TBL] [Abstract][Full Text] [Related]
15. Comparison of reporting phase III randomized controlled trials of antibiotic treatment for common bacterial infections in ClinicalTrials.gov and matched publications. Shepshelovich D; Yelin D; Gafter-Gvili A; Goldman S; Avni T; Yahav D Clin Microbiol Infect; 2018 Nov; 24(11):1211.e9-1211.e14. PubMed ID: 29454846 [TBL] [Abstract][Full Text] [Related]
16. Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis. Chen KY; Borglund EM; Postema EC; Dunn AG; Bourgeois FT Clin Trials; 2022 Aug; 19(4):442-451. PubMed ID: 35482320 [TBL] [Abstract][Full Text] [Related]
17. Comparison between publicly accessible publications, registries, and protocols of phase III trials indicated persistence of selective outcome reporting. Zhang S; Liang F; Li W J Clin Epidemiol; 2017 Nov; 91():87-94. PubMed ID: 28757260 [TBL] [Abstract][Full Text] [Related]
18. Compliance on Mandatory Data Reporting in Registered Obstetrics Trials. Checketts JX; Evans MB; Athale AH; Jawhar OM; Wright MR; Bryant K; Vassar M Am J Perinatol; 2018 Oct; 35(12):1192-1196. PubMed ID: 29695018 [TBL] [Abstract][Full Text] [Related]
20. Public availability of results of trials assessing cancer drugs in the United States. Nguyen TA; Dechartres A; Belgherbi S; Ravaud P J Clin Oncol; 2013 Aug; 31(24):2998-3003. PubMed ID: 23878298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]